COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

COMPASS Pathways has announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first-ever mechanistic study of psilocybin in autistic adults.

Category Press Release
Published in GlobeNewswire

Companies Featured

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.